Neurocrine Bioscience diskutieren
Neurocrine Bioscience
WKN: 900964 / Symbol: NBIX / Name: Neurocrine / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
133,40 €
-0,45 %
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at UBS Group AG from $152.00 to $174.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $182.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Morgan Stanley from $148.00 to $150.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Wedbush from $137.00 to $141.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Piper Sandler from $154.00 to $175.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Stifel Nicolaus from $166.00 to $174.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Morgan Stanley from $150.00 to $158.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at Royal Bank Of Canada from $146.00 to $144.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Morgan Stanley from $158.00 to $163.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Royal Bank Of Canada from $144.00 to $149.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Needham & Company LLC from $161.00 to $170.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at UBS Group AG from $188.00 to $195.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Morgan Stanley from $163.00 to $168.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Piper Sandler from $175.00 to $179.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Royal Bank Of Canada from $156.00 to $160.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Stifel Nicolaus from $174.00 to $183.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Citigroup Inc. from $175.00 to $203.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $172.00 price target on the stock, up previously from $165.00.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at JPMorgan Chase & Co. from $171.00 to $179.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Morgan Stanley from $178.00 to $173.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neueste Beiträge
Guggenheim in Ross Stores Inc. diskutieren